Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Abstract Background and Objective Ibrutinib, an oral Bruton’s tyrosine kinase inhibitor, has demonstrated efficacy as a first-line treatment for chronic lymphocytic leukemia in multiple, phase III, randomized clinical trials. This systematic literature review assessed the clinical effectiveness of i...

Full description

Bibliographic Details
Main Authors: Philip Lee, Kristin D. Kistler, Luc Douyon, Raisa Volodarsky, Alex Young, Sudeep Karve, Swetha Challagulla
Format: Article
Language:English
Published: Adis, Springer Healthcare 2022-12-01
Series:Drugs - Real World Outcomes
Online Access:https://doi.org/10.1007/s40801-022-00332-4

Internet

https://doi.org/10.1007/s40801-022-00332-4

Similar Items